Direct Biologics to go public via a merger with Good Works II Acquisition in a $675m deal.

Direct Biologics, a biotechnology company, agreed to go public via a merger with Good Works II Acquisition, a special purpose acquisition company, in a $675m deal. “The Good Works II team has a long-standing history of working with life sciences companies. We were attracted to Direct Biologics because we believe their technology holds substantial potential as a platform to treat numerous conditions that involve inflammation or that would benefit from the regenerative properties of their proprietary EV technology. We were also impressed that Direct Biologics’ product candidate is in advanced clinical development in an underserved patient population, and was generally well-tolerated and demonstrated clinical activity in multiple investigator-initiated trials for various indications and in a company-sponsored Phase 2 trial in Covid-19 patients with moderate-to-severe ARDS. Direct Biologics also has cGMP manufacturing in place, which we believe positions Direct Biologics to take advantage of the market opportunity if ExoFlo receives either BLA approval or Emergency Use Authorization from the FDA," Cary Grossman Good Works II’s CEO.